UPDATE: Baird Starts MiNK Therapeutics (INKT) at Outperform

November 9, 2021 4:09 AM EST
Get Alerts INKT Hot Sheet
Price: $2.07 -7.59%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 8 | New: 24
Join SI Premium – FREE
(Updated - November 9, 2021 6:21 AM EST)

Baird analyst Jack Allen initiates coverage on MiNK Therapeutics (NASDAQ: INKT) with a Outperform rating and a price target of $26.00.

The analyst comments "We believe iNKT cells have strong potential as a therapeutic modality, given their natural allogeneicity and proven cell killing ability. We are particularly enthusiastic about potential for AGENT-797 in acute GvHD, as the literature provides strong evidence that iNKT levels are implicated in patient outcomes and precedent points to a potentially abbreviated development timeline, while success in solid tumors could drive significant upside over time. With clinical readouts in at least four indications expected over the coming ~12 months, MiNK has a number of ways to win."

For an analyst ratings summary and ratings history on MiNK Therapeutics click here. For more ratings news on MiNK Therapeutics click here.

Shares of MiNK Therapeutics closed at $18.96 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Robert W Baird